Schizophrenia, Bipolar Disorder Linked to Increased Cardiovascular Disease Risk
Researchers estimated the 10- and 30-year risk for cardiovascular disease in patients with serious mental illness.
Researchers estimated the 10- and 30-year risk for cardiovascular disease in patients with serious mental illness.
A panel of 15 experts and stakeholders reviewed findings of a systematic literature search and discussed the impact of the COVID-19 pandemic on mental health care, clinical practice, and management of individuals with schizophrenia and BP-I.
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
Researchers are exploring affective lability as a therapeutic target for bipolar disorder, but limited evidence exists on its prevalence and impact among people with schizophrenia and other psychosis spectrum disorders.
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Investigators evaluated the impact of acute psychosocial stress on changes in amygdala activation and functional connectivity among young adults with bipolar disorder.
Investigators assessed the relationship between clinical and cognitive features and oddball neural deviations across the schizophrenia-bipolar spectrum.
NP expert reviews the top 5 most practical presentations from AANP 2021 with topics ranging from obesity medications and suicide prevention to managing hypertension in diverse populations and cannabinoid use.
ECT treatments helped to reduce symptoms in 4 patients with varying mental illnesses.
Researchers assessed data from short-term studies with open-label extensions among adults and adolescents with bipolar depression to assess the impact of lurasidone on treatment-emergent mania.